Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- SS Innovations International (SSII) Submits FDA Response for SSi Mantra Surgical Robotic SystemLOS ANGELES, CA - October 14, 2026 - SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced that it submitted its response to a request for additional information from the U.S. Food and Drug Administration (FDA) on Oct. 5, 2026, regarding its 510(k) submission for the SSi Mantra surgical robotic system. The response includes final data from an expanded human clinical and human factors validation study, as well as a bridging study completed in August 2026 at Hospital Internacional de Colombia, a member of the Mayo Clinic Care Network. The submission covers the initial indication of cholecystectomy, or gallbladder removal. The company anticipates that the FDA will complete its review of the response and 510(k) submission in the first quarter of 2027, advancing its efforts to introduce the SSi Mantra system to the U.S. market. To view the full press release, visit https://ibn.fm/A6dJ8 About SS Innovations SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates. About the SSi Mantra The SSi Mantra surgical robotic system is a modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that is intended to provide equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart is designed to provide the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
- Portnoy Law Firm Announces Class Action on Behalf of Unicycive Therapeutics, Inc. InvestorsThe Portnoy Law Firm advises Unicycive Therapeutics, Inc., (“Unicycive” or the "Company") (NASDAQ: UNCY) investors of a class action on behalf of investors that bought securities between December 29, 2025 - June 29, 2026, inclusive (the “Class Period”). Unicycive investors have until November 2, 2026 to file a lead plaintiff motion.
- The VIVA FoundationLate-Breaking Clinical Trial Results Announced at VIVA 2026The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced results from Late-Breaking Clinical Trial sessions at VIVA 2026, held at Bellagio...
- Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresectable or Metastatic Hepatocellular CarcinomaElevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients with cancer, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational drug rivoceranib, an oral VEGF-TKI, in combination with camrelizumab, an anti-PD-1 antibody, as a first-line systemic treatment option for unresectable or metastatic hepatocellular carcinoma (uHCC).
- XtalksThe Expanding Peptide Conjugate Landscape: Strategies for Complex Peptide Synthesis, Upcoming Webinar Hosted by XtalksIn this free webinar, learn how synthesis strategies can support the development of increasingly complex peptide conjugates. The featured speaker will discuss route selection, conjugation, purification and analytical methods across peptide-drug, radionuclide, oligonucleotide and...
- New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups� New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposure � Findings build on first positive results where TREMFYA achieved combined fistula remission rates of up to 28% across dosing groups � Results come from the first dedicated Phase 3 randomized, placebo-controlled trial in adults managing Crohn's disease with perianal fistula in more than 20 years Johnson & Johnson today announce... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=362822
- NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug DevelopmentNeOnc (NASDAQ:NTHI) is strengthening its boardroom, as its clinical-development progress seeks to advance treatments for some of the most difficult cancers
- Century Therapeutics, Inc.Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in LondonCentury Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the company will attend the upcoming 2026 Jefferies Global Healthcare Conference in London on November 18, 2026.
- CAMP4 TherapeuticsCAMP4 to Participate in Chardan’s 10th Annual Healthcare ConferenceCAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the company will participate in a panel during Chardan’s 10th Annual Healthcare Conference on October 20, 2026. Details below:
- Tvardi TherapeuticsTvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare ConferenceTvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will present at Chardan’s 10th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026, at 1:30 PM ET.
- Artificial Intelligence in Precision Medicine Market Demand Across Healthcare ApplicationsThe Artificial Intelligence in Precision Medicine Market is entering a high-growth phase as healthcare providers and pharmaceutical companies increasingly use AI to understand disease biology, [read full press release...]
- Microvascular Therapeutics Selected to Present Investment Opportunity at ACQUICON 2026Microvascular Therapeutics, Inc. (“MVT”), a clinical-stage biotechnology company developing next-generation ultrasound imaging and therapeutic technologies, today announced that it has been selected to present in the ACQUICON 2026 Deal Room on Tuesday, October 20, 2026, from 12:30–1:30 p.m. Mountain Time at the Karen Gail Miller Conference Center in Salt Lake City. [PR.com]